Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

BACKGROUND: The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with CHC. Several new treatments including Harvoni, Olysio + Sovaldi, Viekira Pak, Sofosbuvir-based regimens characterized with potent inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sai, Bastian, Nathaniel D., Griffin, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524433/
https://www.ncbi.nlm.nih.gov/pubmed/26239358
http://dx.doi.org/10.1186/s12876-015-0320-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524433/
https://www.ncbi.nlm.nih.gov/pubmed/26239358
http://dx.doi.org/10.1186/s12876-015-0320-4

Ejemplares similares